gefitinib has been researched along with margaric acid in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (margaric acid) | Trials (margaric acid) | Recent Studies (post-2010) (margaric acid) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 90 | 4 | 31 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, J; Huang, X; Ma, B; Ma, T; Shao, G; Wu, P; Xu, C; Yang, S; Yang, X; Yu, Y; Zhang, B; Zhang, L | 1 |
1 other study(ies) available for gefitinib and margaric acid
| Article | Year |
|---|---|
Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistance.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Fatty Acids; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinase; Signal Transduction | 2019 |